Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

The significance of YKL-40 protein in liver fibrosis.

Tao H, Yang JJ, Shi KH, Huang C, Zhang L, Lv XW, Li J.

Inflamm Res. 2014 Apr;63(4):249-54. doi: 10.1007/s00011-013-0698-9. Epub 2014 Jan 19. Review.

PMID:
24442412
2.

YKL-40--an emerging biomarker in cardiovascular disease and diabetes.

Rathcke CN, Vestergaard H.

Cardiovasc Diabetol. 2009 Nov 23;8:61. doi: 10.1186/1475-2840-8-61. Review.

3.

Serum YKL-40 is increased in patients with hepatic fibrosis.

Johansen JS, Christoffersen P, Møller S, Price PA, Henriksen JH, Garbarsch C, Bendtsen F.

J Hepatol. 2000 Jun;32(6):911-20.

PMID:
10898311
4.

Serum YKL-40 in young patients with β-thalassemia major: Relation to hepatitis C virus infection, liver stiffness by transient elastography and cardiovascular complications.

El-Asrar MA, Elbarbary NS, Ismail EA, Elshenity AM.

Blood Cells Mol Dis. 2016 Jan;56(1):1-8. doi: 10.1016/j.bcmd.2015.09.006. Epub 2015 Sep 28.

PMID:
26603717
5.

Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease.

Nøjgaard C, Johansen JS, Christensen E, Skovgaard LT, Price PA, Becker U; EMALD Group..

J Hepatol. 2003 Aug;39(2):179-86.

PMID:
12873813
6.

Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease.

Tran A, Benzaken S, Saint-Paul MC, Guzman-Granier E, Hastier P, Pradier C, Barjoan EM, Demuth N, Longo F, Rampal P.

Eur J Gastroenterol Hepatol. 2000 Sep;12(9):989-93.

PMID:
11007134
7.

A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection.

Berres ML, Papen S, Pauels K, Schmitz P, Zaldivar MM, Hellerbrand C, Mueller T, Berg T, Weiskirchen R, Trautwein C, Wasmuth HE.

J Hepatol. 2009 Feb;50(2):370-6. doi: 10.1016/j.jhep.2008.09.016. Epub 2008 Dec 4.

PMID:
19070929
8.

Plasma YKL-40: a new potential marker of fibrosis in patients with alcoholic cirrhosis?

Johansen JS, Møller S, Price PA, Bendtsen F, Junge J, Garbarsch C, Henriksen JH.

Scand J Gastroenterol. 1997 Jun;32(6):582-90.

PMID:
9200292
9.

Increased immunohistochemical expression of YKL-40 in the spleen of patients with portal hypertension.

Wang D, Lu JG, Wang Q, Du XL, Dong R, Wang P, Zhao L, Jiang X, Yuan LJ.

Braz J Med Biol Res. 2012 Mar;45(3):264-72. Epub 2012 Jan 26.

10.

YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis.

Rath T, Roderfeld M, Güler C, Wenzel C, Graf J, Beitinger F, Roeb E, Zachoval R.

Scand J Gastroenterol. 2011 Nov;46(11):1369-80. doi: 10.3109/00365521.2011.613949. Epub 2011 Sep 12.

PMID:
21905976
11.

Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort: the Boston children's hospital experience.

Lee CK, Perez-Atayde AR, Mitchell PD, Raza R, Afdhal NH, Jonas MM.

J Pediatr. 2013 Oct;163(4):1058-64.e2. doi: 10.1016/j.jpeds.2013.04.044. Epub 2013 Jun 5.

PMID:
23759423
12.

YKL-40 expression in CD14⁺ liver cells in acute and chronic injury.

Pizano-Martínez O, Yañez-Sánchez I, Alatorre-Carranza P, Miranda-Díaz A, Ortiz-Lazareno PC, García-Iglesias T, Daneri-Navarro A, Vázquez-Del Mercado M, Fafutis-Morris M, Delgado-Rizo V.

World J Gastroenterol. 2011 Sep 7;17(33):3830-5. doi: 10.3748/wjg.v17.i33.3830.

13.

Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis.

Furuhashi K, Suda T, Nakamura Y, Inui N, Hashimoto D, Miwa S, Hayakawa H, Kusagaya H, Nakano Y, Nakamura H, Chida K.

Respir Med. 2010 Aug;104(8):1204-10. doi: 10.1016/j.rmed.2010.02.026. Epub 2010 Mar 27.

14.

YKL-40 and hyaluronic acid (HA) as noninvasive markers of liver fibrosis in kidney transplant patients with HCV chronic infection.

Schiavon LL, Carvalho-Filho RJ, Narciso-Schiavon JL, Medina-Pestana JO, Lanzoni VP, Ferraz ML, Silva AE.

Scand J Gastroenterol. 2010 May;45(5):615-22. doi: 10.3109/00365521003637203.

PMID:
20163287
15.

The chitinase-like protein YKL-40 is not a useful biomarker for severe persistent asthma in children.

Santos CB, Davidson J, Covar RA, Spahn JD.

Ann Allergy Asthma Immunol. 2014 Sep;113(3):263-6. doi: 10.1016/j.anai.2014.05.024. Epub 2014 Jun 20.

PMID:
24954373
16.

The chitinase-like protein YKL-40 modulates cystic fibrosis lung disease.

Hector A, Kormann MS, Mack I, Latzin P, Casaulta C, Kieninger E, Zhou Z, Yildirim AÖ, Bohla A, Rieber N, Kappler M, Koller B, Eber E, Eickmeier O, Zielen S, Eickelberg O, Griese M, Mall MA, Hartl D.

PLoS One. 2011;6(9):e24399. doi: 10.1371/journal.pone.0024399. Epub 2011 Sep 20.

17.

YKL-40--a novel biomarker in clinical practice?

Kazakova MH, Sarafian VS.

Folia Med (Plovdiv). 2009 Jan-Mar;51(1):5-14. Review.

PMID:
19437893
18.
19.

YKL-40 and mast cells are associated with detrusor fibrosis in patients diagnosed with bladder pain syndrome/interstitial cystitis according to the 2008 criteria of the European Society for the Study of Interstitial Cystitis.

Richter B, Roslind A, Hesse U, Nordling J, Johansen JS, Horn T, Hansen AB.

Histopathology. 2010 Sep;57(3):371-83. doi: 10.1111/j.1365-2559.2010.03640.x.

PMID:
20840668
20.

YKL-40 expression could be a poor prognostic marker in the breast cancer tissue.

Kang EJ, Jung H, Woo OH, Park KH, Woo SU, Yang DS, Kim AR, Lee JB, Kim YH, Kim JS, Seo JH.

Tumour Biol. 2014 Jan;35(1):277-86. doi: 10.1007/s13277-013-1036-0. Epub 2013 Aug 6.

PMID:
23918300

Supplemental Content

Support Center